APA Zitierstil

Mastellos, D. C., Pires da Silva, B. G. P., Fonseca, B. A. L., Fonseca, N. P., Auxiliadora-Martins, M., Mastaglio, S., . . . Lambris, J. D. (2020). Complement C3 vs C5 inhibition in severe COVID-19: Early clinical findings reveal differential biological efficacy. Clinical immunology (Orlando, Fla.), 220, 108598. https://doi.org/10.1016/j.clim.2020.108598

Chicago Zitierstil

Mastellos, Dimitrios C., et al. "Complement C3 Vs C5 Inhibition in Severe COVID-19: Early Clinical Findings Reveal Differential Biological Efficacy." Clinical Immunology (Orlando, Fla.) 220 (2020): 108598. https://dx.doi.org/10.1016/j.clim.2020.108598.

MLA Zitierstil

Mastellos, Dimitrios C., et al. "Complement C3 Vs C5 Inhibition in Severe COVID-19: Early Clinical Findings Reveal Differential Biological Efficacy." Clinical Immunology (Orlando, Fla.), vol. 220, 2020, p. 108598.